I
nflammatory bowel diseases (IBD) comprising Crohn's disease (CD) and ulcerative colitis (UC) affect an estimated 1.6 million individuals in the United States with as many as 70,000 new patients diagnosed each year. 1 They are complex, relapsing-remitting diseases frequently leading to hospitalizations, surgery, and permanent bowel damage. Advances in therapeutics have increased the number of treatment options, expanding the armamentarium from broad conventional immunomodulator therapy to targeted biologics and small molecules, including monoclonal antibodies to anti-tumor necrosis factor a and gut-specific mucosal integrins. 2, 3 However, this has also resulted in care for IBD becoming increasingly complex and specialized with evolution toward therapeutic paradigms that suggest better outcomes with adoption of upfront biological therapy early on in disease course and in combination with a conventional immunomodulators. 4, 5 Several studies have examined the impact of specialist care on outcomes of patients with IBD. 6, 7 Care at a high IBD volume hospital is associated with lower postoperative mortality among patients undergoing surgery. 8, 9 Among hospitalized patients with UC, gastroenterologist care was associated with lower mortality for up to 1 year after the initial hospitalization compared with admissions under internists and general practitioners. 6 Even in a tertiary referral center, care by gastroenterologists specializing in IBD resulted in superior posthospitalization outcomes and earlier access to IBD-related surgical interventions. 7 The impact of barrier to effective care may extend even before the diagnosis of IBD where a delay may reduce response to medical therapy and increase risk of fibrostenosis and need for surgery. 10, 11 A delay in receiving effective therapy may not be solely due to patient behavior or physician expertise but could also be determined by barriers to access quality IBD care. One such factor that may hinder access to specialist IBD care may be the physical distance from such facilities. Previous studies examining the impact of distance from a hospital have focused on medical or surgical emergencies, demonstrating that in three-quarters of such studies there existed a "distance-decay" relationship with worse outcomes in patients living further away from the site of care. 12 One can envision that distance from care may also be relevant in diseases like IBD that are beset by unpredictable flares, require periodic clinical and endoscopic evaluation to ensure remission, and rely on long-term adherence to therapy that requires a regular patient-provider relationship. Consequently, we performed this study with the aim of examining the impact of distance from area of residence to a referral IBD center on the need for surgery and biological therapy in patients with CD and UC.
METHODS

Study Population
The study cohort consisted of patients recruited for the Prospective Registry in IBD Study at Massachusetts General Hospital (MGH). This prospective cohort is an ongoing registry of patients that is open to all adult patients with an established diagnosis of IBD who received longitudinal care at the MGH. Upon provision of informed consent, all patients completed an enrollment interview with a study research coordinator where demographics, disease characteristics, and history of medical and surgical treatments were obtained. All information was confirmed by medical record review.
Covariates and Outcomes
Our main exposure of interest was distance from zip code of residence to our hospital (MGH). The zip code was obtained from the residential address field of the electronic medical record and distance calculated using a distance calculator (https://www. zip-codes.com/distance_calculator.asp). This distance was modeled in quartiles with the higher quartiles increasingly further away from the hospital. Other covariates obtained include gender, age at enrollment and at diagnosis, disease duration, and smoking status. Disease location and behavior in CD and extent in UC were classified according to the Montreal classification. 13 We also obtained information on education and employment status. Patients reporting a Bachelor's degree or higher were considered "highly educated." Engagement in employment was defined as performing paid work or being a student.
Our primary outcome was need for IBD-related surgery. Our secondary outcomes were need for biological (infliximab, adalimumab, certolizumab, golimumab, natalizumab, or vedolizumab) therapy or immunomodulators (azathioprine, 6-mercaptopurine, methotrexate).
Statistical Analyses
All analyses were performed using Stata 13.0 (StataCorp, College Station, TX). Continuous variables were summarized using means and SDs while categorical variables were expressed as proportions and compared using the chi-square test. We first performed univariate analysis examining the association between distance quartiles and each of our study outcomes. Subsequently, multivariable models were constructed adjusting for diseasespecific covariates, including duration of disease, behavior and extent of involvement, education, and employment status. A P value ,0.05 in this analysis was considered to indicate independent statistical significance. Various sensitivity analyses were performed, excluding patients residing more than 25 and 50 miles away to minimize the potential for bias introduced by a referral population. Approval for this study was obtained from the Institutional Review Board of MGH.
RESULTS
Study Cohort
Our cohort included 2136 patients with IBD (1197 CD, 939 UC) with a mean age of 41 years. Just over half (52%) were women. After excluding patients who lived more than 100 miles away from our hospital (likely representing a referral population) (n ¼ 112), we included 2024 patients in our final analysis. The patients excluded from the study were similar to the final cohort in age and sex, type of IBD, and paid work but were more likely to have CD and be highly educated compared with included patients. Dividing the cohort into quartiles based on proximity, the mean distance from zip code of residence to our hospital was 2.5 miles (61.4), 8.8 miles (62.6), 22.0 miles (65.0), and 50.8 miles (616.5) for the first, second, third, and fourth quartiles, respectively. There were no differences in sex, type of IBD, location or behavior of CD, perianal involvement, and extent of UC between patients living near or far from our hospital ( Table 1) . Patients with a greater distance to the hospital were slightly older, were diagnosed with IBD at an older age, had a longer duration of disease, and were more likely to have a history of smoking. They were also less likely to be doing paid work or have a Bachelor's degree or higher.
Distance from Hospital and Disease Outcomes
Patients living in the most distant quartile were significantly more likely to need IBD-related surgery than those living closer to the hospital (OR, 2.44; 95% CI, 1.80-3.32) ( Table 2 and Fig. 1) . A dose-response relationship was seen with progressively greater likelihood for surgery in quartiles 2 (OR, 1.68; 95% CI, 1.23-2.28) and 3 (OR, 1.94; 95% CI, 1.44-2.62). A similar relationship was also noted in biological therapy where patients in the most distant quartile had a 2-fold increase in need in comparison with patients living near the hospital (OR, 2.19; 95% CI, 1.69-2.85). For immunomodulator use, a significantly elevated OR was noted only among patients in the most distant quartile compared with those living the closest (OR, 1.69; 95% CI, 1.29-2.22); no effect was noted in the second and third quartiles.
These findings remained significant on our multivariable analysis. Each progressively further quartile was associated with a greater need for surgery in all IBD patients adjusting for age, type of IBD, duration of disease, and engagement in paid employment. Patients residing in the most distant quartile were 2 times as likely to need surgery as those residing closest to the hospital (OR, 1.98; 95% CI, 1.36-2.89). This relationship also persisted in the need for biological therapy (Q4 versus Q1: OR, 2.18; 95% CI, 1.60-2.97) and for the most distant quartile the need for immunomodulator therapy (Q4 versus Q1: OR, 1.61; 95% CI, 1.19-2.21). Similar results were obtained when distance from the hospital was modeled as a continuous variable with each 10-mile increase in distance being associated with an increased risk for surgery (OR, 1.09; 95% CI, 1.03-1.16; P ¼ 0.004) and biological therapy (OR, 1.14; 95% CI, 1.08-1.20; P , 0.001).
Subgroup Analysis
We performed subgroup analysis by type of IBD. In CD, additionally adjusting for the perianal involvement and disease location and behavior, higher quartiles of distance were associated with an increasing likelihood of surgery and biological therapy (Table 3) . For example, patients living in the most distant quartile had a 2-fold increase in need for surgery (OR, 1.75; 95% CI, 1.04-2.97) and biological therapy (OR, 2.40; 95% CI, 1.54-3.75). A similar effect was also noted in UC, additionally adjusting for disease extent. There was a 3-fold greater need for surgery (OR, 3.31; 95% CI, 1.34-8.88) and 2-fold increase in biological therapy (OR, 2.02; 95% CI, 1.22-3.33) between the most distant and closest quartiles.
Sensitivity Analysis
To further minimize referral bias where patients with more aggressive disease are referred to us for specialized care, we performed sensitivity analysis excluding patients who lived 50 miles or more from our hospital. This showed a similar effect on multivariable analysis as with our primary analysis. All 3 outcomes remained statistically significant with an increasing likelihood of surgery (OR, 1.82; 95% CI, 1.20-2.79), biological therapy (OR, 2.55; 95% CI, 1.78-3.65), and immunomodulator therapy (OR, 1.76; 95% CI, 1.22-2.54) between the most distant and closest quartiles.
DISCUSSION
Treatment of IBD is complex and increasingly specialized. With expansion of the number of treatment options, therapeutic drug monitoring, and recognition of more robust treatment goals The mean distance from our hospital was 2.5, 8.8, 22.0, and 50.8 miles for the first (most proximal) through fourth (most distant), respectively. Bold indicates P , 0.05.
such as early attainment of mucosal healing, management of IBD increasingly requires close and frequent contact between the patient and the treatment team, with dynamic alterations of therapeutic strategies. However, physical access to specialized health care is not always easy and patients frequently have to travel long distances to receive such care, which in turn may affect initiation and optimization of medical therapy. The impact of travel distance from a referral IBD hospital on patients' outcomes has not been examined previously. In a study from a single referral center, we demonstrated that greater distance from specialized care was associated with a higher risk for IBD-related surgery and need for biological or immunomodulator therapy. Our findings were robust to a range of assumptions of distances travelled excluding referral patients and on adjustment for various disease-related characteristics.
A few previous studies have examined the impact of specialized care on patients with IBD. 6, 8, 9, 14 Murthy et al 6 assessed the impact of gastroenterologist care and observed a 3-to 4-fold lower mortality among hospitalized UC patients when under the care of a gastroenterologist. A similar result was seen in studies assessing the impact of hospital volume on outcomes of IBD-related hospitalizations. IBD patients undergoing surgery at high IBD volume admission centers had lower in-hospital and postoperative mortality. 8, 9, 15 Even within a single referral hospital, implementation of specialized IBD care pathway and dedicated care by a gastroenterologist specializing in IBD was associated with higher rates of remission at 3 months and facilitated early surgical intervention. 7 Equivalent results were observed in studies assessing the influence of specialized care in other diseases. [16] [17] [18] [19] [20] Thus overall, evidence suggests that the best outcomes in IBD may be obtained in specialized setting, particularly for patients at risk for more severe disease or requiring complex multidisciplinary care.
The impact of travel distance on patient outcomes has been examined before for other indications and elegantly summarized in a systematic review by Kelly et al. 12 Over three-quarters of the examined studies demonstrated a distance-decay association with worse outcomes in individuals living further away from health care facilities. In our study, distance from the referral hospital was associated with greater need for surgery, immunomodulator, and biological therapy. Greater travel distance may affect need for surgery in patients with IBD by impeding early initiation of effective treatment. Though in our study the findings for biological or immunomodulator therapy may be inverse to what one may expect, with patients residing close to the hospital more likely to be initiated on biological therapy, this may not capture the effect of timing of initiation of such therapy. Although there are robust data supporting the efficacy of biological therapy in reducing surgery and hospitalizations in IBD, the timing of initiation of such therapy seems to be key. Previous studies have demonstrated that delayed initiation of biological or immunomodulator therapy, particularly after chronic bowel damage and fibrostenosing complications have set in, may not result in an optimal benefit. [21] [22] [23] [24] [25] Longer distance from the hospital may also affect patient adherence to treatment by impeding a robust patient-provider relationship, which exerts a strong influence on adherence to recommendations. [26] [27] [28] Nonadherence in turn has been associated with worse outcomes in IBD. 29 Longer distance may also interfere with ongoing monitoring using serologic markers, endoscopies, and drug levels, thereby not allowing optimization of therapy. We readily acknowledge a few sources of bias that may influence interpretation of our study results. First, it is possible that patients residing furthest away from hospital are referred to us for more severe disease. This is unlikely to be the sole explanation for our findings for a few reasons. First, our findings remained significant on restricting travel distances to within 25 or 50 miles, and it is unlikely that patients within this proximal vicinity are referral cases alone. Second, at our center, patients are recruited into our patient registry after the third visit (often later) to our offices and are not one-time consultation referrals. A third limitation is that we did not have information on the duration of disease at immunomodulator or biological initiation. It is important for future studies to be able to address for this and account for delay in initiation of effective treatment. We also acknowledge some limitations in our study. Although we focused on a hard endpoint of surgery that contributes significant weight to disease damage indices like the Lemann index, it is also important to examine additional endpoints such as early attainment of mucosal healing using "treat-to-target" strategies.
There are a few implications to our findings. Several studies have proposed centralization of health care services to improve outcomes, minimize regional differences in the quality of care, and reduce costs. 30, 31 However, often centralized high-volume centers offering specialized care are necessarily located in large metropolitan centers, leading to increased travel distance (and consequently reduced access) for patients residing in less populated areas further away. 32 As demonstrated in our study, this increased travel distance may result in worse patient outcomes or reduce the benefit of getting specialized care. Although it may be logistically difficult for most of complex IBD care to be restricted to a few specialized centers, it is of greater importance to define what components of specialized IBD care are associated with improved patient outcomes and to replicate such care in the community. The development of quality metrics by professional societies and organizations [33] [34] [35] is an important step in that regard. Education of care providers at all levels, from gastroenterologists to primary care physicians, mid-level providers, and nurses including those specializing in IBD, would also help provide optimal high-quality IBD care to all patients. Another solution to overcome the challenge of physical distance may be wider use of technology to deliver specialized care through telemedicine. Several models exist demonstrating the feasibility and value of such care for providing both patient care and provider education. Efficient delivery of high-quality specialized IBD care attains particular importance with rising IBD-related health care costs. Early, effective therapy that decreases the likelihood of disease damage is important in reducing IBD-related costs over the lifetime of a patient. In conclusion, we demonstrated that greater distance from a referral IBD hospital was associated with greater need for IBDrelated surgery, immunomodulator, and biological therapy. There is need for further studies to determine how specialized IBD care may be provided in a decentralized way to optimize patient outcomes.
